Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B.


Emory, collaborators testing antiviral drug as potential treatment for coronaviruses

February 3, 2020

An antiviral compound discovered at Emory University could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.





Shot-49-Flu-Virus

Georgia Bio honors Emory drug innovator with Georgia Bio Community Award

January 30th, 2017

Georgia Bio has honored Abel De La Rosa, PhD, chief scientific officer of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD) with a 2017 Community Award.


vlcsnap-5897981

NPR’s Closer look examines DRIVE and EIDD

04/02/2016

David Perryman of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development discusses the institute and how it ranks nationwide.


vlcsnap-5897981

DRIVE CEO George Painter hiking in Death Valley

03/31/2016

DRIVE CEO George Painter hiking in Death Valley, California- pictured in Spring, 2016 furthering DRIVE’s mission by bridging the Valley of Death.



IconZirus2

Emory Scientists Developing Drugs To Treat Zika Virus

February 19th, 2016

More than 20 scientists with two drug development groups at Emory University are working to develop a treatment for the Zika virus.